[CLRB] Cellectar Biosciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.33 Change: 0.12 (9.92%)
Ext. hours: Change: 0 (0%)

chart CLRB

Refresh chart

Strongest Trends Summary For CLRB

CLRB is in the long-term down -83% below S&P in 1 year and down -100% below S&P in 19 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and cha

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-67.91% ROE-161.51% ROI
Current Ratio1.23 Quick Ratio Long Term Debt/Equity0.21 Debt Ratio1.29
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities Cash From Investing Activities-30 K Cash From Operating Activities-2.37 M Gross Profit
Net Profit-2.3 M Operating Profit-2.59 M Total Assets10.91 M Total Current Assets7.26 M
Total Current Liabilities5.9 M Total Debt460 K Total Liabilities6.32 M Total Revenue
Technical Data
High 52 week11.8 Low 52 week1.29 Last close2 Last change-8.26%
RSI42.66 Average true range0.31 Beta0.38 Volume446.49 K
Simple moving average 20 days-13.38% Simple moving average 50 days-14.66% Simple moving average 200 days-14.94%
Performance Data
Performance Week-10.91% Performance Month-17.7% Performance Quart5.26% Performance Half-18.03%
Performance Year-81.13% Performance Year-to-date29.03% Volatility daily8.24% Volatility weekly18.43%
Volatility monthly37.78% Volatility yearly130.87% Relative Volume319.58% Average Volume519.25 K
New High New Low

News

2019-05-21 08:30:00 | Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131

2019-05-20 16:10:17 | Cellectar Biosciences Announces Closing of $10.0 Million Financing

2019-05-18 07:15:48 | 5 Biotech Stocks to Watch in the Second Half of 2019

2019-05-16 08:52:36 | Cellectar Biosciences Announces $10.0 Million Financing

2019-05-15 08:30:00 | CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma

2019-05-13 08:00:00 | Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma

2019-05-06 08:00:00 | Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update

2019-05-02 14:18:14 | 5 Biotech Stocks With Near-Term Catalysts Ahead

2019-04-29 10:20:00 | Cellectar Biosciences, Inc. NASDAQ:CLRB: Are Analysts Right About The Drop In Earnings?

2019-04-10 13:40:13 | 5 Oncology Companies That Are Set to Run

2019-03-19 08:30:00 | FDA Grants Exemption to Import Alert for Cellectar’s CLR 131 in Pediatric and Adolescent Patients

2019-02-26 08:30:00 | Cellectar Reports Financial Results for Year Ended December 31, 2018 and Provides a Corporate Update

2019-02-25 08:30:00 | Cellectar Reports Positive Top-line Response Rate of 30% from R/R Multiple Myeloma Cohort in Ongoing Phase 2 Study of CLR 131

2019-02-05 08:30:00 | Cellectar Biosciences to Present at the Annual BIO CEO & Investor Conference

2019-01-23 08:00:00 | Cellectar Biosciences to Present at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference

2019-01-22 14:15:00 | What Kind Of Shareholders Own Cellectar Biosciences, Inc. NASDAQ:CLRB?

2019-01-07 08:30:00 | Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma

2019-01-03 08:30:00 | Cellectar Biosciences to Present at the Biotech Showcase

2018-12-11 08:30:00 | Cellectar Granted Japanese Patent for CLR 131

2018-12-04 08:30:00 | Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma

2018-11-21 14:53:36 | Analysts Take Action on Health Care Stocks

2018-11-13 08:30:00 | Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update

2018-11-12 08:30:00 | Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies

2018-10-02 08:00:00 | Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma

2018-09-27 08:30:00 | Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference

2018-09-27 08:00:00 | Today's Research Reports on Trending Tickers: Onconova Therapeutics and Cellectar Biosciences

2018-09-25 08:30:00 | Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

2018-09-24 08:00:00 | Cellectar Biosciences Provides an Update on the FDA Import Alert

2018-09-17 08:43:00 | Cellectar stock surges 15% premarket after FDA fast tracks treatment for rare childhood cancer

2018-09-17 08:30:00 | FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Osteosarcoma

2018-08-29 08:30:00 | Cellectar Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

2018-08-20 08:30:00 | Fractionated Dosing Improves Tolerability and Safety of Cellectar’s CLR 131 in R/R Multiple Myeloma Patients

2018-08-13 09:25:57 | Benzinga Pro's 5 Stocks To Watch Today

2018-08-13 08:00:00 | Cellectar’s CLR 131 Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing’s Sarcoma

2018-08-10 08:00:00 | Cellectar Reports 2018 Second Quarter Financial Results and Provides Business Update

2018-08-01 08:30:00 | Cellectar and Orano Med Announce Collaboration to Develop New Phospholipid Drug Conjugate

2018-07-31 16:05:00 | Cellectar Biosciences Announces Closing of $16.56 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

2018-07-27 08:30:00 | Cellectar Biosciences Announces Pricing of $14.4 Million Underwritten Public Offering 

2018-07-18 08:20:00 | Today's Research Reports on Trending Tickers: Cara Therapeutics and Cellectar Biosciences

2018-07-18 08:00:00 | Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients

2018-07-17 13:25:00 | Cellectar Biosciences shares surge 15% on results of one cancer patient in mid-stage trial

2018-07-17 12:04:26 | Cellectar Shares Climb After Strong Trial Response For Rare Blood Cancer Drug

2018-07-17 08:00:00 | Cellectar Reports 94% Reduction in Overall Tumor Volume in Waldenstrom Macroglobulinemia Patient in Phase 2 CLR 131 Clinical Study

2018-07-13 16:05:00 | Cellectar Announces 1-for-10 Reverse Stock Split

2018-07-09 08:00:00 | Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for Treatment of Ewing’s Sarcoma

2018-06-28 08:00:00 | Cellectar Announces Expansion of Diffuse Large B-Cell Lymphoma Cohort in CLR 131 Phase 2 Trial

2018-06-07 08:30:00 | Cellectar Granted U.S. Patent for the Treatment of Various Cancers and Cancer Stem Cells with CLR 131

2018-06-06 08:00:00 | FDA Grants Rare Pediatric Disease Designation to Cellectar Biosciences’ CLR 131 for the Treatment of Rhabdomyosarcoma

2018-05-11 08:00:00 | Cellectar Reports Recent Corporate Highlights and 2018 First Quarter Financial Results

2018-05-09 14:28:39 | Cellectar Granted Orphan Drug Designation for CLR 131 to Treat Rhabdomyosarcoma